COST-EFFECTIVENESS OF OFATUMUMAB COMPARED WITH OTHER DISEASE-MODIFYING THERAPIES FOR THE TREATMENT OF RELAPSING MULTIPLE SCLEROSIS IN GREECE

被引：0

作者：

Petropoulos, A. ^{[1
]}

Cooney, P. ^{[2
]}

Patidar, M. ^{[3
]}

Gudala, K. ^{[3
]}

Tiwari, S. ^{[4
]}

Brennan, R. ^{[2
]}

Kapsogeorgiou, K. ^{[1
]}

Cheilas, G. ^{[1
]}

Banhazi, J. ^{[5
]}

机构：

[1] Novartis Hellas SACI, Athens A1, Greece

[2] Novartis Ireland Ltd, Dublin, Ireland

[3] Novartis Healthcare Private Ltd, Hyderabad, India

[4] Novartis Healthcare Private Ltd, Hyderabad, Andhra Pradesh, India

[5] Novartis Pharma AG, Basel, BS, Switzerland

来源：

VALUE IN HEALTH | 2022年 / 25卷 / 12期

关键词：

D O I：

暂无

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

EE143

引用

页码：S80 / S81

页数：2

共 50 条

[31] Stick or twist? Cost-effectiveness of siponimod compared with continuing existing disease-modifying therapies in the treatment of active secondary progressive multiple sclerosis in the UK [J].

Montgomery, S. ;

Woodhouse, F. ;

Vudumula, U. ;

Gudala, K. ;

Duddy, M. ;

Kroes, M. .

JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) :669-678

[32] The Shifting Landscape of Disease-Modifying Therapies for Relapsing Multiple Sclerosis [J].

Burton, Jodie M. ;

Freedman, Mark S. .

JOURNAL OF NEURO-OPHTHALMOLOGY, 2018, 38 (02) :210-216

[33] Peginterferon beta-1a versus other self-injectable disease-modifying therapies in the treatment of relapsing-remitting multiple sclerosis in Scotland: a cost-effectiveness analysis [J].

Hernandez, Luis ;

Guo, Shien ;

Toro-Diaz, Hector ;

Carroll, Stuart ;

Farooq, Syed Feisal Syed .

JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (03) :228-238

[34] Cost-Effectiveness Analysis of Ofatumumab for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada [J].

Moogeh Baharnoori ;

Virender Bhan ;

Fraser Clift ;

Kimberly Thomas ;

Soukaïna Mouallif ;

Nicholas Adlard ;

Philip Cooney ;

François Blanchette ;

Barkha P. Patel ;

Daniel Grima .

PharmacoEconomics - Open, 2022, 6 :859-870

[35] Cost-Effectiveness Analysis of Ofatumumab for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada [J].

Baharnoori, Moogeh ;

Bhan, Virender ;

Clift, Fraser ;

Thomas, Kimberly ;

Mouallif, Soukaina ;

Adlard, Nicholas ;

Cooney, Philip ;

Blanchette, Francois ;

Patel, Barkha P. ;

Grima, Daniel .

PHARMACOECONOMICS-OPEN, 2022, 6 (06) :859-870

[36] Disease modifying therapies in multiple sclerosis: cost-effectiveness systematic review [J].

Eduardo Navarro, Cristian ;

Ordonez-Callamand, Eliana ;

Pablo Alzate, Juan .

FARMACIA HOSPITALARIA, 2020, 44 (02) :68-76

[37] Cost-utility and cost-effectiveness analysis of disease-modifying drugs of relapsing–remitting multiple sclerosis: a systematic review [J].

Nasrin Abulhasanbeigi Gallehzan ;

Majid Khosravi ;

Khosro Jamebozorgi ;

Nazanin Mir ;

Habib Jalilian ;

Samira Soleimanpour ;

Saeed Hoseini ;

Aziz Rezapour ;

Abbas Eshraghi .

Health Economics Review, 14

[38] Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom [J].

Timothy Spelman ;

William L. Herring ;

Yuanhui Zhang ;

Michael Tempest ;

Isobel Pearson ;

Ulrich Freudensprung ;

Carlos Acosta ;

Thibaut Dort ;

Robert Hyde ;

Eva Havrdova ;

Dana Horakova ;

Maria Trojano ;

Giovanna De Luca ;

Alessandra Lugaresi ;

Guillermo Izquierdo ;

Pierre Grammond ;

Pierre Duquette ;

Raed Alroughani ;

Eugenio Pucci ;

Franco Granella ;

Jeannette Lechner-Scott ;

Patrizia Sola ;

Diana Ferraro ;

Francois Grand’Maison ;

Murat Terzi ;

Csilla Rozsa ;

Cavit Boz ;

Raymond Hupperts ;

Vincent Van Pesch ;

Celia Oreja-Guevara ;

Anneke van der Walt ;

Vilija G. Jokubaitis ;

Tomas Kalincik ;

Helmut Butzkueven .

PharmacoEconomics, 2022, 40 :323-339

[39] Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom [J].

Spelman, Timothy ;

Herring, William L. ;

Zhang, Yuanhui ;

Tempest, Michael ;

Pearson, Isobel ;

Freudensprung, Ulrich ;

Acosta, Carlos ;

Dort, Thibaut ;

Hyde, Robert ;

Havrdova, Eva ;

Horakova, Dana ;

Trojano, Maria ;

De Luca, Giovanna ;

Lugaresi, Alessandra ;

Izquierdo, Guillermo ;

Grammond, Pierre ;

Duquette, Pierre ;

Alroughani, Raed ;

Pucci, Eugenio ;

Granella, Franco ;

Lechner-Scott, Jeannette ;

Sola, Patrizia ;

Ferraro, Diana ;

Grand'Maison, Francois ;

Terzi, Murat ;

Rozsa, Csilla ;

Boz, Cavit ;

Hupperts, Raymond ;

Van Pesch, Vincent ;

Oreja-Guevara, Celia ;

van der Walt, Anneke ;

Jokubaitis, Vilija G. ;

Kalincik, Tomas ;

Butzkueven, Helmut .

PHARMACOECONOMICS, 2022, 40 (03) :323-339

[40] The Cost of Multiple Sclerosis and the Cost Effectiveness of Disease-Modifying Agents in its Treatment [J].

Ceri J. Phillips .

CNS Drugs, 2004, 18 :561-574

← 1 2 3 4 5 →